Editorial Comment From Dr. Miyake to Effects of Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma

Documenti analoghi

• Editorial Comment to “Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma”
  di: Nozomi Hayakawa, et al.
  Pubblicazione: (2025)
• Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma
  di: Satoshi Inoue, et al.
  Pubblicazione: (2025)
• Editorial Comment From Dr. Miyake to Effects of Robot‐Assisted Radical Cystectomy on Peritoneal Carcinomatosis and Prognosis in Patients With Muscle‐Invasive Bladder Cancer: A Multicenter Retrospective Study
  di: Makito Miyake
  Pubblicazione: (2025)
• Editorial Comment to “Clinical Features and Risk Factors of Enfortumab Vedotin‐Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study ( YUSHIMA Study)”
  di: Makito Miyake
  Pubblicazione: (2026)
• Editorial Comment from Dr Miyake to α1‐blockers as a risk factor for hypotension in combination with oral 5‐aminolevulimic acid for photodynamic diagnosis in patients with bladder cancer
  di: Makito Miyake
  Pubblicazione: (2025)